Article
Entecavir maleate versus entecavir in Chinese chronic hepatitis B predominantly genotype B or C: Results at week 144.
Journal of viral hepatitis - 1 Oct 2017
Xu J-H, Wang S, Xu Z-N, Yu Y-Y, Si C-W, Zeng Z, Li J, Mao Q, Zhang D-Z, Tang H, Sheng J-F, Chen X-Y, Ning Q, Shi G-F, Xie Q, Zhang X-Q, Dai J
Abstract excerpt
Reports on the efficacy and safety of long-term entecavir treatment in chronic hepatitis B (CHB) predominantly genotype B or C are insufficient. This study presents the efficacy and safety of entecavir maleate in Chinese CHB patients. Patients were randomly assigned to receive 48-week treatment with either 0.5 mg/day entecavir (group A) or 0.5 mg/day entecavir maleate (group B), and then all patients received...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.